Publications
137 results found
Rogers DF, 2004, Mucus Hypersecretion in COPD, Recent Advances in Pathophysiology of COPD, Editors: Barnes, Pages: 101-119, ISBN: 9783764369149
Culpitt SV, Rogers DF, Fenwick PS, et al., 2003, Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD., Thorax, Vol: 58, Pages: 942-946, ISSN: 0040-6376
The pathophysiology of chronic obstructive pulmonary disease (COPD) features pulmonary inflammation with a predominant alveolar macrophage involvement. Bronchoalveolar macrophages from patients with COPD release increased amounts of inflammatory cytokines in vitro, an effect that is not inhibited by the glucocorticosteroid dexamethasone. Resveratrol (3,5,4'-trihydroxystilbene) is a component of red wine extract that has anti-inflammatory and antioxidant properties. A study was undertaken to determine whether or not resveratrol would inhibit cytokine release in vitro by alveolar macrophages from patients with COPD.
Rogers DF, 2003, Pulmonary mucus: Pediatric perspective, PEDIATRIC PULMONOLOGY, Vol: 36, Pages: 178-188, ISSN: 8755-6863
- Author Web Link
- Cite
- Citations: 22
Rogers DF, 2003, Airway hypersecretion in allergic rhinitis and asthma: New pharmacotherapy, CURRENT ALLERGY AND ASTHMA REPORTS, Vol: 3, Pages: 238-248, ISSN: 1529-7322
- Author Web Link
- Cite
- Citations: 17
Nightingale JA, Rogers DF, Barnes PJ, 2003, How to design a negative study, CHEST, Vol: 123, Pages: 656-656, ISSN: 0012-3692
Culpitt SV, Rogers DF, Shah P, et al., 2003, Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 167, Pages: 24-31, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 227
Rogers DF, 2003, The airway goblet cell, INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, Vol: 35, Pages: 1-6, ISSN: 1357-2725
- Author Web Link
- Cite
- Citations: 154
Donnelly LE, Rogers DF, 2003, Antiproteases and retinoids for treatment of chronic obstructive pulmonary disease, Exp Opinion Therapeutic Drugs, Vol: 13, Pages: 1345-1372, ISSN: 1354-3776
Donnelly LE, Rogers DF, 2003, Therapy for chronic obstructive pulmonary disease in the 21st century, DRUGS, Vol: 63, Pages: 1973-1998, ISSN: 0012-6667
- Author Web Link
- Cite
- Citations: 66
Rogers DF, 2002, Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 32, Pages: 1124-1127, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 50
Rogers DF, 2002, Pharmacological regulation of the neuronal control of airway mucus secretion, CURRENT OPINION IN PHARMACOLOGY, Vol: 2, Pages: 249-255, ISSN: 1471-4892
- Author Web Link
- Cite
- Citations: 42
Culpitt SV, de Matos C, Russell RE, et al., 2002, Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 165, Pages: 1371-1376, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 129
Nightingale JA, Rogers DF, Barnes PJ, 2002, Comparison of the effects of salmeterol and formoterol in patients with severe asthma, CHEST, Vol: 121, Pages: 1401-1406, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 25
de Graaf W, Smith AK, Barnes PJ, et al., 2002, Mucin gene expression in human respiratory epithelial cell lines: Activation by phorbol esters and effect of a corticosteroid and cyclic AMP activating agents, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 135, ISSN: 0007-1188
Rogers DF, 2002, Mucoactive drugs for asthma and COPD: any place in therapy?, EXPERT OPINION ON INVESTIGATIONAL DRUGS, Vol: 11, Pages: 15-35, ISSN: 1354-3784
- Author Web Link
- Cite
- Citations: 36
Nightingale JA, Rogers DF, 2002, Should drugs affecting mucus properties be used in COPD? Clinical evidence, Clinical management of chronic obstructive pulmonary disease, Editors: al, Pages: 405-425, ISBN: 9780824706104
Pritchard K, Smith AK, Rogers DF, 2002, Measuring mucin gene expression in human airways - Northern analysis and RT-PCR, Thorac Med, Vol: 17, Pages: 1-9
Fox E, Griesenbach U, Rogers DF, et al., 2001, Successful oligodeoxynucleotide transfer to the airway epithelium following intravenous delivery, THORAX, Vol: 56, Pages: 2-2, ISSN: 0040-6376
Rogers DF, 2001, Motor control of airway goblet cells and glands, RESPIRATION PHYSIOLOGY, Vol: 125, Pages: 129-144, ISSN: 0034-5687
- Author Web Link
- Cite
- Citations: 109
Khan S, Liu YC, Khawaja AM, et al., 2001, Effect of the long-acting tachykinin NK<sub>1</sub> receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 132, Pages: 189-196, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 10
Smith AK, Rogers DF, 2001, In vivo models of airway goblet cell hyperplasia and mucin gene expression, Cilia and Mucus: From Development to Respiratory Defence, Editors: Salathe, Pages: 239-251, ISBN: 9780824704414
Pritchard K, Smith AK, Rogers DF, 2001, Measurement of airway mucin gene expression, Human Airway Inflammation: Sampling Techniques and Analytical Protocols, Editors: Donnelly, Pages: 285-294, ISBN: 9780896039230
Rogers DF, 2001, Muscarinic control of airway mucus secretion, Muscarinic Receptors in Airway Diseases, Editors: al, Pages: 175-201, ISBN: 9783764359881
Rogers DF, Barnes PJ, 2001, Mucus regulation, New Drugs for Asthma, Allergy and COPD, Editors: Barnes, Pages: 160-164, ISBN: 9783805568623
Rogers DF, 2001, Tachykinin receptor antagonists for asthma and COPD, Expert Opin Ther Patients, Vol: 11, Pages: 1097-1121, ISSN: 1354-3776
Rogers DF, 2001, Mucus hypersecretion in chronic obstructive pulmonary disease, CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PATHOGENESIS TO TREATMENT, Vol: 234, Pages: 65-83, ISSN: 1528-2511
- Author Web Link
- Cite
- Citations: 41
Smith AK, Rogers DF, 2001, In vivo models of airway goblet cell hyperplasia and mucin gene expression, 2nd International Meeting on Cilia, Mucus, and Mucociliary Interactions, Publisher: MARCEL DEKKER, Pages: 239-251
- Author Web Link
- Cite
- Citations: 1
Donnelly LE, 2001, Human Airway Inflammation: Sampling techniques and analytical protocols, ISBN: 9780896039230
Rogers DF, 2000, Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy., Monaldi Arch Chest Dis, Vol: 55, Pages: 324-332, ISSN: 1122-0643
Patients with chronic obstructive pulmonary disease (COPD) exhibit characteristics of airway mucus hypersecretion, including sputum production, increased luminal mucus, goblet cell hyperplasia and submucosal gland hypertrophy. These features are not common to all patients and the impact of hypersecretion on morbidity and mortality is a matter for debate. However, current evidence indicates that airway hypersecretion has pathophysiological and clinical significance in COPD, particularly as patients age or are prone to respiratory tract infection. This suggests that it is important to develop drugs that inhibit mucus hypersecretion in these patients. A number of drugs are currently available that may be of therapeutic benefit in hypersecretory disorders of the airways, e.g. glucocorticosteroids and anticholinergics. Novel compounds are undergoing preclinical research, e.g. inhibitors of epidermal growth factor receptor tyrosine kinase and antisense oligomers. However, preliminary data indicate that the mucus in COPD differs to that in asthma in that: 1) it is less viscous and without marked plasma exudation, 2) the ratio of mucin (MUC) 5AC:MUC5B may be reduced, and 3) there is full release of mucin into the airway lumen rather than "tethering" of mucus as in asthma. Consequently, future research should determine whether there really is an intrinsic abnormality specific to mucus in chronic obstructive pulmonary disease. Based upon this information, appropriate suppressers of mucus hypersecretion in chronic obstructive pulmonary disease can be developed.
Nightingale JA, Maggs R, Cullinan P, et al., 2000, Airway inflammation after controlled exposure to diesel exhaust particulates, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 162, Pages: 161-166, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 200
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.